Dr. Garassino is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5841 S Maryland Ave
# MC2115
Chicago, IL 60637Phone+1 773-702-2984
Summary
- Dr. Marina Chiara Garassino is a physician in Chicago, IL. She is the Director of the Thoracic Oncology program at the University of Chicago Medical Center. She received her medical degree from Università degli Studi di Milano and has practiced for 26 years. She is experienced in lung cancer and thoracic oncology. She has 300 publications and 39870 citings. She is the leading author of some of the most important research in lung cancer and in thymic malignancies.
Education & Training
Università degli Studi di MilanoClass of 1995
Certifications & Licensure
IL State Medical License 2020 - 2026
Clinical Trials
- Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Start of enrollment: 2017 Mar 02
- Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. Start of enrollment: 2018 May 23
- Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma Start of enrollment: 2018 Oct 30
Publications & Presentations
PubMed
- DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer.Christine M Bestvina, Jared H L Hara, Theodore Karrison, Benjamen Bowar, Janet Chin
Clinical Lung Cancer. 2024-12-01 - Epigenomic exploration of disease status of EGFR-mutated non-small cell lung cancer using plasma cell-free DNA hydroxymethylomes.Yong Peng, Jason Karpus, Jyoti D Patel, Everett E Vokes, Marina Chiara Garassino
Cancer Communications. 2024-11-11 - 1 citationsCTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2024-11-01
Press Mentions
WCLC 2024: Normalised Membrane Ratio of TROP2 by Quantitative Continuous Scoring Predictive of Clinical Outcomes in TROPION-Lung 01September 9th, 2024- Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients with Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 TrialSeptember 8th, 2024
- Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring Predictive of Clinical Outcomes in TROPION-Lung 01September 8th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
